Primary headache disorders summary
|Chronic headache disorders:||Chronic cluster headache
Chronic tension-type headache
Chronic paroxysmal hemicrania
Episodic tension-type headache
|Prevalence:||3% of the general population have chronic headache,
defined as ≥15 headache days per month for at least three months
|ICD-10:||G44.02 Chronic cluster headache
G43.7 Chronic migraine without aura
G44.22 Chronic tension-type headache
G44.04 Chronic taroxysmal hemicrania
G34.D Abdominal migraine
G43.A Cyclical vomiting
G44.21 Episodic tension-type headache
Headaches are among the most prevalent neurological disorders1
Headaches are one of the most frequent neurological disorders seen in primary care and neurology practices.1 50% of individuals report having at least one headache each year.2 Primary headaches, including migraine headaches, affect more than 36 million Americans.3 In one survey, approximately 14% of US adults reported having a migraine or severe headache in the previous three months.4
The three common forms of primary headache disorders are tension-type headache, migraine, and cluster headache. The most frequently encountered form of secondary headaches is medication-overuse headache, which may affect between 1 and 2% of the general population and is most commonly seen as a complication of chronic headache therapy.5 Overall, the prevalence of migraine in the U.S. population is 1%.6
Headaches affect roughly 80 million U.S. adults each year.1,2
Migraine and other headache disorders represent a major public health burden
Migraine is the reason for 0.5% of all ambulatory care visits and headaches in general are the fourth leading cause of emergency department visits.4 The prevalence of migraine is highest in females ages 18-44 years, where it represents a major public health burden.7 It is also more common in households with lower annual incomes.6
Individuals with common migraine and other headache disorders have significantly compromised physical and social function when compared to the general population and to patients with other chronic conditions.8 Preventive drugs for migraine, the second most prevalent primary headache disorder, are underutilized in clinical practice.9 Proper recognition and treatment, including patient education and the use of acute, prophylactic and biobehavioral therapies have the potential to improve the health-related quality of life of patients with chronic headache disorders.10
The MIDAS tool can help you assess quality of life for patients with primary headache disorders
A clinical decision support (CDS) notification will display during the patient visit if your patient’s medical history matches potential clinical markers of migraine or other primary headache disorders.
From the CDS notification you’ll be able to access the migraine disability assessment (MIDAS) tool, a brief self-administered questionnaire designed to efficiently measure the impact of migraine and other primary headache disorders on patients’ lives and to quantify headache related disability.11
- National Institute of Neurologic Disorders and Stroke. Headache Information Page. https://www.ninds.nih.gov/Disorders/All-Disorders/Headache-Information-Page-358. Accessed July 7, 2017.
- World Health Organization. Headache Disorders Fact Sheet. http://www.who.int/mediacentre/factsheets/fs277/en/. Updated April 2016. Accessed July 7, 2017.
- American Migraine Foundation. Learn more. https://americanmigrainefoundation.org/about/. Accessed July 7, 2017.
- Burch RC, Loder S, Loder E, et al. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015;551:21–34.
- Smith TR, Stoneman J. Medication overuse headache from antimigraine therapy: clinical features, pathogenesis and management. Drugs. 2004;64:2503–2514.
- Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the american migraine prevalence and prevention study. Headache. 2012;52:1456–1470.
- Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache. 2013;53:427–436.
- Terwindt GM, Ferrari MD, Tijhuis M, et al. The impact of migraine on quality of life in the general population: the GEM study. Neurology. 2000;55:624–629.
- Silberstein, SD. Preventive Migraine Treatment. Continuum (Minneap Minn). 2015;21:973–989.
- Bordini CA, Mariano da Silva H, Garbelini RP, et al. Effect of preventive treatment on health-related quality of life in episodic migraine. J Headache Pain. 2005;6:387–391.
- Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56:S20-8.